Charles River Laboratories International, Inc. (CRL) fair value analysis
S&P 500 · Updated 2026-08-30
Forward Fair Value verdict
OvervaluedBased on TickrTrends' weekly Forward Fair Value model, CRL is trading at more than a 25% premium to estimated fair value.
- Last price
- $291.50
- Sector
- Healthcare
- 12-month range
- $161.25–$232.51
What our data shows for CRL
- Our model validated 17 trailing price-to-earnings windows for CRL, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $161.25–$232.51.
- The 14-day relative strength index sits at an overbought 74.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CRL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.